Approximately 61.3% and 23.4% of trials included participants with hemophilia A and hemophilia B, respectively, and 14.5% included both those with hemophilia A and B. Additionally, 21.0% of trials included participants with inhibitors (alloantibodies directed against FVIII or FIX), and most trials (>75%) were conducted among those with severe or moderate/severe hemophilia. Here, F8 is linked to hemophilia B.